Acquisition of Vishal Surgicals and Vishal Surgicals & Medicals, a Partnership Firm, through its subsidiary company Sai Pharma Distributors Private Limited through Slump Sale / Business ....
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 2.4 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Entero Healthcare Solutions held its Board meeting on May 25, 2026, approving audited standalone and consolidated financial results for Q4 and FY26. Consolidated revenue grew 29% to Rs 65,912 million from Rs 50,958 million, while standalone revenue declined 15% to Rs 3,482 million from Rs 4,087 million. Consolidated profit after tax rose 36% to Rs 1,458 million from Rs 1,074 million. The Board also reappointed three Independent Directors for a second term, allotted 7,240 equity shares under ESOP plan, and granted 7,300 fresh options. The key corporate action is the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals through subsidiary Sai Pharma Distributors Private Limited via Slump Sale/Business Transfer Agreement, expanding the company's pharma distribution network.
Strong consolidated earnings growth demonstrates successful integration of multiple subsidiaries acquired during FY26. The Vishal Surgicals acquisition through the subsidiary network aligns with Entero's inorganic growth strategy and could contribute to FY27 revenues. Positive auditor opinion supports financial reporting quality.